Details of the Drug

General Information of Drug (ID: DM1BKA6)

• Drug Name: Opicapone
• Synonyms: BIA-9-1067

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  N04BX04: Opicapone
  N04BX: Other dopaminergic agents
  N04B: DOPAMINERGIC AGENTS
  N04: ANTI-PARKINSON DRUGS
  N: NERVOUS SYSTEM
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 413.2
  Logarithm of the Partition Coefficient (xlogp); 3.4
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
  Bioavailability: The bioavailability of drug is 64% [2]
  Clearance: The total body clearance of drug is 22 L/h [3]
  Elimination: Following administration of a single 100 mg dose of radiolabeled opicapone in healthy subjects, about 70% of the total dose was recovered in feces, where 22% of the recovered dose was excreted as an unchanged parent drug [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 61.6 hours [4]
  Vd: The volume of distribution (Vd) of drug is 29 L [3]
• Chemical Identifiers:
  Formula: C15H10Cl2N4O6
  IUPAC Name: 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
  Canonical SMILES: CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
  InChI: InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
  InChIKey: ASOADIZOVZTJSR-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 135565903
  ChEBI ID: CHEBI:134699
  CAS Number: 923287-50-7
  UNII: Y5929UIJ5N
  DrugBank ID: DB11632
  TTD ID: D01SGK
  ACDINA ID: D01302

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Catechol-O-methyl-transferase (COMT)	TTKWFB8	COMT_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
UDP-glucuronosyltransferase 1A1	OTH1C8OJ	UD11_HUMAN	Gene/Protein Processing	[5]
UDP-glucuronosyltransferase 1A10	OTOTZVEY	UD110_HUMAN	Gene/Protein Processing	[5]
UDP-glucuronosyltransferase 1A7	OTY4JJ32	UD17_HUMAN	Gene/Protein Processing	[5]
UDP-glucuronosyltransferase 1A8	OTTMABBG	UD18_HUMAN	Gene/Protein Processing	[5]
UDP-glucuronosyltransferase 1A9	OTPCHAFX	UD19_HUMAN	Gene/Protein Processing	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Parkinson disease
• ICD Disease Classification: 8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Catechol-O-methyl-transferase (COMT)	DTT	COMT	9.24E-02	0.17	1.09

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Opicapone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Opicapone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[6]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Opicapone and Esketamine.	Depression [6A70-6A7Z]	[7]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Opicapone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[8]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Opicapone and Lasmiditan.	Migraine [8A80]	[9]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Erythrosine sodium anhydrous	E00324	27872	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Amaranth	E00228	13506	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Opicapone 50 mg capsule	50 mg	Capsule	Oral
Opicapone 25 mg capsule	25 mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] FDA Approved Drug Products: Pifeltro (doravirine) oral tablets
• [3] Summary of Product Characteristics: Ongentys (opicapone) oral capsules
• [4] FDA Approved Drug Products: ONGENTYS (opicapone) capsules, for oral use
• [5] In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms. Toxicol Lett. 2022 Aug 15;367:3-8. doi: 10.1016/j.toxlet.2022.07.003. Epub 2022 Jul 8.
• [6] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [7] Cerner Multum, Inc. "Australian Product Information.".
• [8] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [9] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.